Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 28 March 2013 | By Louise Zornoza,
In draft guidance released on 27 March 2013, the UK's National Institute for Health and Clinical Excellence (NICE) declined to recommend National Health Service coverage of Pfizer's Xalkori (crizotinib).
Crizotinib is a tyrosine kinase inhibitor (TKI), and works by blocking enzymes that otherwise could stimulate cancerous growth. Crizotinib blocks a specific enzyme called anaplastic lymphoma kinase (ALK) which is present in some non-small-cell lung cancers. Although the drug was found to provide an additional 5.1 months in progression free survival over the comparator lung cancer drug (docetaxel), NICE determined that the drug is not cost effective, as it does not meet its criteria to qualify as an "end of life" drug.
NICE will normally recommend reimbursement for treatments that cost around £20,000 to £30,000 per quality life year (QALY) or less. If a drug meets the criteria to be considered an end of life treatment, there is no set threshold cost per QALY. However, the highest cost per QALY of an end of life recommended drug has been around £50,000. The Committee concluded that the most plausible cost per QALY would lie somewhere between £63,800 and £181,100 for crizotinib compared with docetaxel, and between £51,700 and £80,500 for crizotinib compared with best supportive care.
Commenting on the decision, NICE Chief Executive Sir Andrew Dillon said: "We have already recommended a number of treatments for the various stages of non-small-cell lung cancer. However, although the independent committee that considered the evidence found crizotinib to be clinically effective treatment for ALK-positive non-small-cell lung cancer, even if the supplementary advice to the Committee for life-extending treatments had applied, crizotinib could not be considered a cost-effective use of NHS."
Tags: Pfizer, UK
Regulatory Focus newsletters
All the biggest regulatory news and happenings.